ketoconazole has been researched along with Neoplasm Metastasis in 24 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Excerpt | Relevance | Reference |
---|---|---|
"These results indicate that ketoconazole significantly reduced hepatic metastases from the human pancreatic carcinoma RWP-2 in the nude mouse model, and inhibited thromboxane B2 formation, potentiating a concomitant redirection of platelet endoperoxide metabolism into PGD2, PGE2, and 6-keto-F1a." | 3.71 | The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. ( Krambovitis, E; Tsatsakis, AM; Tzanakakis, GN; Vezeridis, MP, 2002) |
"Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy." | 2.73 | Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. ( Brown, MA; Do, KA; Logothetis, CJ; Millikan, RE; Moomey, B; Pagliaro, LC; Wen, S, 2008) |
"Fixed dosing was found to be feasible, without increased variability of clearance or neutrophil toxicity compared to BSA-based dosing." | 2.73 | A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. ( Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP, 2008) |
"Ketoconazole action dosed as 400-600 g per day was studied in 12 patients with prostatic metastasizing carcinoma." | 2.67 | [Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma]. ( Morávek, P; Zita, K, 1991) |
"Almost all patients with prostatic cancer will eventually escape the control of the first-line endocrine therapy and relapse." | 2.38 | Management of relapsing disease in prostate cancer. ( Denis, L; Mahler, C, 1992) |
"Prednisone use was associated with a reduced risk of progression on docetaxel in the propensity score-weighted multivariable Cox model (P=0." | 1.43 | The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. ( Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA, 2016) |
"Invasion and metastasis are responsible for 90% of cancer-related mortality." | 1.42 | 4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model. ( Bracke, ME; De Ryck, T; Katritzky, AR; Patronov, A; Roman, BI; Slavov, SH; Stevens, CV; Vanhoecke, BW, 2015) |
"Ketoconazole (KT) is a less potent CYP17 inhibitor previously widely used in mCRPC." | 1.40 | Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. ( Alimohamed, N; Atenafu, EG; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Seah, JA; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE, 2014) |
"Ketoconazole can suppress androgen production and has a beneficial role in the hormonal therapy of patients with prostate cancer who have not undergone orchiectomy." | 1.27 | High-dose ketoconazole therapy in patients with metastatic prostate cancer. ( Al-Sarraf, M; Decker, DA; Kresge, C; Subramanian, MG; Tapazoglou, E, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (29.17) | 18.7374 |
1990's | 5 (20.83) | 18.2507 |
2000's | 4 (16.67) | 29.6817 |
2010's | 8 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Roman, BI | 1 |
De Ryck, T | 1 |
Patronov, A | 1 |
Slavov, SH | 1 |
Vanhoecke, BW | 1 |
Katritzky, AR | 1 |
Bracke, ME | 1 |
Stevens, CV | 1 |
Almassi, N | 1 |
Reichard, C | 1 |
Li, J | 1 |
Russell, C | 1 |
Perry, J | 1 |
Ryan, CJ | 2 |
Friedlander, T | 1 |
Sharifi, N | 1 |
Leibowitz-Amit, R | 1 |
Seah, JA | 1 |
Atenafu, EG | 1 |
Templeton, AJ | 1 |
Vera-Badillo, FE | 1 |
Alimohamed, N | 1 |
Knox, JJ | 1 |
Tannock, IF | 1 |
Sridhar, SS | 1 |
Joshua, AM | 1 |
Kim, W | 1 |
Zhang, L | 1 |
Wilton, JH | 1 |
Fetterly, G | 1 |
Mohler, JL | 1 |
Weinberg, V | 1 |
Morse, A | 1 |
Szmulewitz, RZ | 1 |
Friedlander, TW | 1 |
Fong, L | 1 |
Lin, AM | 1 |
Harzstark, AL | 1 |
Molina, A | 1 |
Small, EJ | 2 |
Teply, BA | 1 |
Luber, B | 1 |
Denmeade, SR | 1 |
Antonarakis, ES | 1 |
Millikan, RE | 1 |
Wen, S | 1 |
Pagliaro, LC | 1 |
Brown, MA | 1 |
Moomey, B | 1 |
Do, KA | 1 |
Logothetis, CJ | 1 |
Figg, WD | 1 |
Woo, S | 1 |
Zhu, W | 1 |
Chen, X | 1 |
Ajiboye, AS | 1 |
Steinberg, SM | 1 |
Price, DK | 1 |
Wright, JJ | 1 |
Parnes, HL | 1 |
Arlen, PM | 1 |
Gulley, JL | 1 |
Dahut, WL | 1 |
Pond, GR | 1 |
Armstrong, AJ | 1 |
Galsky, MD | 1 |
Wood, BA | 1 |
Leopold, L | 1 |
Sonpavde, G | 1 |
Lin, GW | 1 |
Yao, XD | 1 |
Ye, DW | 1 |
Zhu, Y | 1 |
Zhang, SL | 1 |
Dai, B | 1 |
Zhang, HL | 1 |
Shen, YJ | 1 |
Ma, CG | 1 |
Tzanakakis, GN | 1 |
Krambovitis, E | 1 |
Tsatsakis, AM | 1 |
Vezeridis, MP | 1 |
Yong, WP | 1 |
Wang, LZ | 1 |
Tham, LS | 1 |
Wong, CI | 1 |
Lee, SC | 1 |
Soo, R | 1 |
Sukri, N | 1 |
Lee, HS | 1 |
Goh, BC | 1 |
Spors, S | 1 |
Möller, A | 1 |
Baron, AD | 1 |
Fippin, L | 1 |
Apodaca, D | 1 |
Bare, RL | 1 |
Torti, FM | 1 |
Rickman, T | 1 |
Garmany, R | 1 |
Doherty, T | 1 |
Benson, D | 1 |
Okusa, MD | 1 |
Mahler, C | 1 |
Denis, L | 1 |
Morávek, P | 1 |
Zita, K | 1 |
Lowe, FC | 1 |
Bamberger, MH | 1 |
Tapazoglou, E | 1 |
Subramanian, MG | 1 |
Al-Sarraf, M | 1 |
Kresge, C | 1 |
Decker, DA | 1 |
Oelschläger, H | 1 |
Rothley, D | 1 |
Dunzendorfer, U | 1 |
Eichenberger, T | 1 |
Trachtenberg, J | 1 |
Debruyne, FM | 1 |
Witjes, FA | 1 |
Castillo Cádiz, O | 1 |
Martínez Sanz, P | 1 |
Dubost, JJ | 1 |
Sauvezie, B | 1 |
Ristori, JM | 1 |
Thevenet, JP | 1 |
Rampon, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate[NCT00002855] | Phase 3 | 306 participants (Actual) | Interventional | 1996-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 reviews available for ketoconazole and Neoplasm Metastasis
Article | Year |
---|---|
Endocrine therapy of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti | 1998 |
Management of relapsing disease in prostate cancer.
Topics: Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Estrogens | 1992 |
[New hormonal treatments of metastatic prostatic cancer. Review of the literature].
Topics: Aminoglutethimide; Androgen Antagonists; Animals; Antineoplastic Agents; Combined Modality Therapy; | 1985 |
7 trials available for ketoconazole and Neoplasm Metastasis
Article | Year |
---|---|
Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgens; Androstenes; Humans; Ketoconazole; Male; Mi | 2014 |
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Ag | 2008 |
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Interacti | 2010 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Hu | 2013 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-R | 2008 |
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy | 1997 |
[Results of a clinical trial of ketoconazole in metastatic prostatic carcinoma].
Topics: Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms | 1991 |
14 other studies available for ketoconazole and Neoplasm Metastasis
Article | Year |
---|---|
4-Fluoro-3',4',5'-trimethoxychalcone as a new anti-invasive agent. From discovery to initial validation in an in vivo metastasis model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Cell Movement; Ce | 2015 |
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Topics: Aged; Alleles; Androgen Antagonists; Biomarkers, Tumor; Gain of Function Mutation; Gene Expression R | 2018 |
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free S | 2016 |
The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
Topics: Aged; Humans; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms | 2012 |
The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis.
Topics: 6-Ketoprostaglandin F1 alpha; Adenocarcinoma; Animals; Antineoplastic Agents; Dinoprostone; Humans; | 2002 |
[Malignant hemangiopericytoma. Candida meningitis under ketoconazole therapy].
Topics: Adult; Candidiasis; Female; Hemangiopericytoma; Humans; Ketoconazole; Leukopenia; Meningitis; Neopla | 1983 |
Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma.
Topics: ACTH Syndrome, Ectopic; Adenocarcinoma; Adrenocorticotropic Hormone; Aged; Alkalosis; Comorbidity; C | 2001 |
Indications for use of ketoconazole in management of metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Contraindications; Estrogens; Humans; Ketoconazol | 1990 |
High-dose ketoconazole therapy in patients with metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androstenedione; Combined Modality Therapy; Dehydroepiandrosterone; Dexamethas | 1986 |
[Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents; Biological Availability; Bi | 1988 |
Effects of high-dose ketoconazole in patients with androgen-independent prostatic cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Alkaline Phosphatase; Humans; Ketoconazole; Male; Middle | 1988 |
Ketoconazole high dose (H.D.) in the management of hormonally pretreated patients with progressive metastatic prostate cancer.
Topics: Estrogens; Humans; Hydrocortisone; Ketoconazole; Male; Neoplasm Metastasis; Orchiectomy; Prostatic N | 1987 |
[Ketoconazole in the treatment of advanced cancer of the prostate: experience with 14 patients].
Topics: Acid Phosphatase; Aged; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neop | 1985 |